ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) Files An 8-K Results of Operations and Financial Condition

ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02. Results of Operations and Financial Condition.

On April 17, 2017, OncoMed Pharmaceuticals, Inc. (the Company)
announced its cash and short-term investment balance for the
quarter ended March 31, 2017. The full text of the press release
issued in connection with the announcement (the Press Release) is
furnished as Exhibit 99.1 to this Current Report on Form 8-K and
is located on the Companys website at www.oncomed.com under
Investors Press Releases.

The information in Item 2.02 of this Current Report on Form 8-K
(including Exhibit 99.1) shall not be deemed filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference under the Securities
Act of 1933, as amended, except as expressly set forth by
specific reference in such a filing, regardless of any general
incorporation language in any such filing, unless the Company
expressly sets forth in such filing that such information is to
be considered filed or incorporated by reference therein.

Item 8.01. Other Events.

On April 17, 2017, in the Press Release, the Company also
announced top-line results from the Companys randomized
145-patient Phase 2 PINNACLE clinical trial of tarextumab
(anti-Notch2/3, OMP-59R5) in combination with etoposide plus
either cisplatin or carboplatin chemotherapy in previously
untreated patients with extensive-stage small cell lung cancer,
as well as a conference call/webcast to review these results. The
Company further reported in the Press Release that it will
discontinue enrollment in the Phase 1b clinical trial of
brontictuzumab (anti-Notch1, OMP-52M51) in combination with
trifluridine/tipiracil (Lonsurf) in third-line colorectal cancer
patients.The first, third, and fifth paragraphs of the Press
Release are incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.





Press release dated April 17, 2017 entitled OncoMeds
Phase 2 Trial of Tarextumab in Small Cell Lung Cancer
Does Not Meet Endpoints


OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company’s Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company’s Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.


ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) closed its last trading session up +0.12 at 4.84 with 586,666 shares trading hands.

An ad to help with our costs